Clinical data | |
---|---|
Trade names | Imbruvica, others |
Other names | PCI-32765, CRA-032765 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a614007 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth (capsules) |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 97.3% |
Metabolism | Liver (CYP3A & CYP2D6) |
Elimination half-life | 4–6 hours |
Excretion | Feces (80%), urine (10%) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C25H24N6O2 |
Molar mass | 440.507 g·mol−1 |
3D model (JSmol) | |
| |
|
Ibrutinib, sold under the brand name Imbruvica among others, is a medication used to treat mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and Waldenström's macroglobulinemia.[4][5] It is used in MCL and CLL when other treatments have failed.[5] Other uses may include graft versus host disease.[4] It is taken by mouth.[4]
Common side effects include low platelets, low red blood cells, low white blood cells, diarrhea, rash, bleeding, and mouth inflammation.[4] Other side effects may include infection, heart failure, high blood pressure, other cancers, and tumor lysis syndrome.[4] Use in pregnancy may harm the baby.[4] It works by blocking Bruton's tyrosine kinase (BTK) which slows B cell division.[5]
Ibrutinib was approved for medical use in the United States in 2013 and Europe in 2014.[6][5] It is on the World Health Organization's List of Essential Medicines as a complementary item.[7] Generic versions have been approved.[8] In the United Kingdom 4 weeks of treatment costs the NHS about £5,000 as of 2021.[9] This amount in the United States costs about 14,500 USD.[10]
References
edit- ^ "Ibrutinib (Imbruvica) Use During Pregnancy". Drugs.com. 3 December 2019. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
- ^ "Imbruvica 140 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC)". (emc). 16 January 2020. Archived from the original on 28 March 2020. Retrieved 28 March 2020.
- ^ "UK Ibrutinib label". UK Electronic Medicines Compendium. 25 August 2016. Archived from the original on 30 July 2019. Retrieved 3 October 2021.
- ^ a b c d e f g h i j "Imbruvica- ibrutinib capsule Imbruvica- ibrutinib tablet, film coated". DailyMed. 8 April 2020. Archived from the original on 12 August 2020. Retrieved 21 April 2020.
- ^ a b c d e f "Imbruvica EPAR". European Medicines Agency (EMA). 8 July 2021. Archived from the original on 10 April 2021. Retrieved 14 July 2021.
- ^ "Ibrutinib Monograph for Professionals". Drugs.com. Archived from the original on 10 July 2020. Retrieved 24 November 2021.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ "Ibrutinib: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 24 June 2021. Retrieved 19 June 2021.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1028. ISBN 978-0857114105.
- ^ "Imbruvica Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 13 September 2021. Retrieved 24 November 2021.